Modified FOLFOX

DRUG3 trials

Conditions

Advanced Solid TumorBile Duct CancerCholangiocarcinomaLocally Advanced or Metastatic Small Bowel AdenocarcinomaMetastatic CancerMetastatic Colorectal CancerSolid CarcinomaSolid Tumor

Phase 1

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

TerminatedNCT05346484

Imugene LimitedAdvanced Solid Tumor, Bile Duct Cancer, Cholangiocarcinoma +4

Start: 2022-05-17End: 2026-01-12Updated: 2026-03-06

Phase 2

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

CompletedNCT00636610

Genentech, Inc.Metastatic Colorectal Cancer

Start: 2008-05-31End: 2010-12-31Updated: 2017-06-08

Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma

RecruitingNCT06278545

Centre Hospitalier Universitaire DijonLocally Advanced or Metastatic Small Bowel Adenocarcinoma

Start: 2024-02-16End: 2029-02-28Target: 130Updated: 2024-02-26

Cancer Research2024-04-05

Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.

Journal of Clinical Oncology2024-01-201 citations

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.

2023-11-104 citations

730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumors

Regular and Young Investigator Award Abstracts2023-10-31

Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases

Journal for ImmunoTherapy of Cancer2023-04-0121 citations

Modified FOLFOX

Sponsors

Conditions

Phase 1

Phase 2

Related Papers